Clinical Trials
12
Active:0
Completed:8
Trial Phases
3 Phases
Phase 2:1
Phase 3:9
Phase 4:2
Drug Approvals
12
FDA:12
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 3
9 (75.0%)Phase 4
2 (16.7%)Phase 2
1 (8.3%)A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 855
- Registration Number
- NCT02886702
- Locations
- 🇺🇸
Fougera Investigational Site, San Antonio, Texas, United States
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 1110
- Registration Number
- NCT02886715
- Locations
- 🇺🇸
Fougera Investigational Site, Austin, Texas, United States
Study to Determine the Pharmacokinetics of Product 0405
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Product 0405
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Registration Number
- NCT02176577
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Product 0405Drug: Placebo for Product 0405
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Registration Number
- NCT02176538
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo for Product 0405Drug: Product 0405
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Registration Number
- NCT02176551
- Prev
- 1
- 2
- 3
- Next
News
No news found